Business Context and Reporting Period
Pulse Biosciences, Inc. (PLSE), a Delaware corporation, filed this Form 8-K on August 6, 2026. The report details the entry into a material definitive agreement regarding an equity distribution program.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on the authorization of a potential capital raise.
- Maximum Offering Size: Up to $75,000,000 in aggregate offering price.
- Commission Rate: Up to 3.0% of the gross sales price of shares sold.
- Sales Agent: Mizuho Securities USA LLC.
Material Changes
On August 6, 2026, the Company entered into an Equity Distribution Agreement (the "Sales Agreement") with Mizuho. This agreement allows the Company to sell shares of its common stock from time to time through "at the market" offerings. The Company is not obligated to sell any shares and may suspend solicitations at any time.
Guidance, Outlook, and Risks
The filing does not provide financial guidance or management commentary on future performance. Key terms and contingencies include:
- Sale Method: Shares may be sold via ordinary brokers' transactions, directly on The Nasdaq Capital Market, to market makers, or through negotiated transactions.
- Pricing: Sales will be made at prevailing market prices, prices related to market prices, or negotiated prices.
- Registration: The offering is made pursuant to an effective Form S-3 registration statement (File No. 333-293596) declared effective on February 27, 2026.
- Legal Opinion: Validity of the issuance is supported by an opinion from Baker & Hostetler LLP.
Investor Verification Checklist
- Verify the current market price of PLSE common stock to assess potential dilution impact.
- Review the full text of the Equity Distribution Agreement (Exhibit 1.1) for specific termination rights and conditions.
- Check the Company's latest 10-K or 10-Q for current cash balances to determine the necessity of this capital raise.
- Monitor future filings for actual sales volumes and proceeds generated under this agreement.